Leptomeningeal Metastases

Bousquet G, et al.  Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer   J Clin Oncol 44:8894, 2014.  (FULL TEXT)
Hofer S., et al.  Intrathecal Trastuzumab: Dose Matters  Acta Oncol 51:955-6, 2012. (FULL TEXT)

Colozza M., et al.  Extended Survival of a HER2-positive Metastatic Breast Cancer Patient with Brain Metastases also Treated with Intrathecal Trastuzumab   Cancer Chemother Pharmacol 63:1157-9, 2009.

 M. Kak et al  Treatment of Leptomeningeal Carcinomatosis: Current Challenges and Future Opportunities  J Clin Neurosci  April 2015;22(4):632-7   

Tanaka et al  Response of Meningeal Carcinomatosis from Breast Cancer to Capecitabine Monotherapy: A Case Report   Cancer Treat Rev 2013 Nov 39(7):720-7 

B. Scott and S Kesari  Leptomeningeal Metastases in Breast Cancer  Eur J Pharmacol 2013 Oct 5 717(1-3):84-7

J. Jung et al  Incidence and Risk Factors for Leptomeningeal Carcinomatosis in Breast Cancer Patients with Parenchymal brain metastases  J Korean Neurosurg Soc  2012 Sept:53(3)193-9 

Debra Schwab Brandt. Intrathecal trastuzumab: 46 months and no progression, Community Oncology, July 2012.  (case report)

S. Lee et al   Leptomeningeal Metastases from Breast Cancer: Intrinsic Subtypes may Affect Unique Clinical Manifestations   Breast Cancer Research and Treatment   2011 129: 809-817

M. Oliviera et al Complete Response in HER2+ Leptomeningeal Carcinomatosis from Breast Cancer with Intrathecal Trastuzumab Breast Cancer Research and Treatment 2011 (127):841-844.  (case report)

H. Onishi et al Objective Response with Lapatinib in Patients with Meningitis Carcinomatosa Derived from HER2/HER1-Negative Breast Cancer International Journal of Clinical Oncology, 2011 Feb 15. (case report)

M. Chamberlain Leptomeningeal Metastasis  Seminars in Neurology Jul 2010 30(30):236-44.

J. Grewal et al  Isolated Loss of Hormonal Receptors in Leptomeningeal Metastasis From Estrogen Receptor– and Progesterone Receptor–Positive Lobular Breast Cancer JournalofClinical Oncology May 1 2010 28(13):e200-2. (case report)

H. Gauthier et al  Survival of Breast Cancer Patients with Meningeal Carcinomatosis  Annals of Oncology April 29 2010.

P. Feyer et al   DEGRO Practical Guidelines for Palliative Radiotherapy of Breast Cancer Patients: Brain Metastases and Leptomeningeal Carcinomatosis. Strahlenther Onkologie Feb 2010 186(2):63-9.

A. Hoffmann et al  Neoplastic Meningitis from Breast Cancer: Feasibility and Activity of Long-Term Intrathecal Liposomal Ara-C Combined with Dose-Dense Temozolmide Anticancer Research Dec 2009 29(12):5191-5. (case report)

R. Soffietti et al  The Role of Intra-Cerebrospinal Fluid Treatment and Prophylaxis in Patients with Solid Tumors  Seminal Oncology Aug 2009 36 (4 Suppl 2):S55-68

F. Waki et al  Prognostic Factors and Clinical Outcomes in Patients with Leptomeningeal Metastasis from Solid Tumors  Journal of Neurooncol Jun 2009 93(2):205-1

W. Shapiro et al  Treatment Modalities for Leptomeningeal Metastases  Seminal Oncology Aug 2009 36(4 Suppl 2):S46-54

P. Gaviani et al  Neoplastic Meningitis from Breast Carcinoma with Complete Response to Liposomal Cytarabine: Case Report  Neurol Science June 2009 30(3):251-54.  (case report)

O. Mir et al  High-Dose Intrathecal Trastuzumab (Herceptin) for Leptomeningel Metastases Secondary to Her-2 Overexpressing Breast Cancer  Ann Oncol Nov 2008 19(11):1978-80.  (case report)

M. Glas et al  Liposomal Cytarabine Given Concomitantly with Radiotherapy in a Patient with Leptomeningeal Metastasis from Breast Cancer  Journal of Neurol Nov 2008 255(11):1838-9.  (case report)

 Drappatz and Batchelor  Leptomeningeal Neoplasms Current Treatment Options Neurology, July 2007; 9(4):283-293 

H. Stemmler, K Mengele, V. Heinemann Intrathecal Trastuzumab (Herceptin) and Methotrexate for Meningeal Carcinomatosis in HER2-Overexpressing Metastatic Breast Cancer: A Case Report   Anti Cancer Drugs,  2008; 19:832-836.  (case report)

E. Kaal and C. Vecht CNS Complications of Breast Cancer Current and Emerging Treatment Options CNS Drugs, 2007; 21: 559-579 (570-571).

L. Rogers, M. Chamberlain, and M. Glantz Evidenced-Based Review of Intrathecal Chemotherapy in Outcomes of Patients with Leptomeningeal Metastasis  Journal of Clinical Oncology ASCO Annual Meeting Proceedings Part 1 Abstract 1529 June 20, 2006 (supplement); 24: 18S (also see poster discussion at Central Nervous Systems Tumors).

H. Stemmler, M. Schmitt, N. Harbeck et al Application of Intrathecal Trastuzumab (Herceptin) for Treatment of Meningeal Carcinomatosis in HER2-Overexpressing Metastatic Breast Cancer Oncology Reports, 2006; 15: 1373-1377.  (case report)

S. Tailibert, Laigle-Donadey, F. Chodkiewicz et al Leptomeningeal Metastases form Solid Malignancy: a Review Neurosurgery, March 2005; 75: 85-99.

N. Lin, J. Bellon and E. Winer CNS Metastases in Breast Cancer Journal of Clinical Oncology, September 1, 2004; 22 (17): 3608-3617 (3614).

L. Rogers, S. Remer, and S. Teuwani Durable Response of Breast Cancer Leptomeningeal Metastasis to Capecitabine (Xeloda) Monotherapy Neuro-Oncology, January 2004; 6: 63-64.  (case report)

M. Ozdogan, M. Samur, H. Bozcuk et al Durable Remission of Leptomeningeal Metastasis of Breast Cancer with Letrozole (Femara): a Case Report and Implications of Biomarkers on Treatment Selection. Japanese Journal of Clinical Oncology, 2003; 33: 229-231.  (case report)

E. Chang and S. Lo Diagnosis and Management of Central Nervous System Metastases from Breast Cancer The Oncologist, October, 2003; 8 (5) 398-410 (9-10).

S. Berg and M Chamberlain Systemic Chemotherapy, Intrathecal Chemotherapy, and Symptom Management in the Treatment of Leptomeningeal Metastasis   Current Oncology Report, Jan 5 2003; 1:29-40.  

B. Gordon and J. Myers  Leptomeningeal Metastases Clinical Journal of Oncology Nursing, March-April 2003; 7 (2): 151-55.